FDA approves 3 Teligent topical generics

SILVER SPRING, Md. — The Food and Drug Administration approved three generics from New Jersey-based specialty generics company Teligent on the last day of 2016, the company announced Tuesday. 

 

The approvals were for the company’s generics of triamcinolone acetonide ointment, 1000,000 units/gram and 1mg/gram; clindamycin phosphate topical solution 1%; and flurandrenolide ointment, 0.05%. 

 

The company said that this brings its portfolio of internally developed topical generics that received approval in 2016 to nine, and that the three products approved have an addressable market of about $73.6 million.